Overview

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Status:
Terminated

Trial end date:
2020-04-02

Target enrollment:

Participant gender:

Summary

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.

Phase:

Phase 2

Details

Lead Sponsor:

F-star Therapeutics, Inc.
Spring Bank Pharmaceuticals, Inc.

Collaborator:

PRA Health Sciences

Treatments:

Tenofovir